Welcome to
Chemical Collective

Are you 18 or older?

Please confirm that your are 18 years of age or older.

You are not allowed to access the page.

I am 18+

EXIT

SALE NOW ON!

PSYCH NEWS – 11/08/2025

By David Blackbourn

CYB003 Receives Regulatory Approval for MDD
The Minnesota Psychedelic Medicine Task Force
Psychedelics Beneficial for the Clergy?
Experimental Psychedelics for Life-Threatening Diagnoses
Psychedelics Help LGBTQ+ Identity and Wellbeing
Australia’s Clinical Practice Guideline for MDMA
Rising Ketamine Addiction in the UK
The Brain on Psychedelics: Psilocybin vs Ketamine
Final Thoughts

7 minute read

0 Last updated August 11th, 2025

By David Blackbourn

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chemical Collective or any associated parties.

This week’s psych news sees major developments across the board, from landmark clinical trials in Europe to bold policy recommendations in Australia and the US. New findings from around the world continue to reveal the wide-ranging benefits of psychedelics, including anxiety treatment, addiction therapy, and spiritual wellbeing, and even acceptance of gender identity. The psychedelic renaissance continues apace.

CYB003 Receives Regulatory Approval for MDD

On August 7th, Cybin, a leader in developing differentiated, next-generation therapeutics, received European regulatory approval to begin its Phase 3 EMBRACE study in Ireland, Greece, and Poland. The study has already been approved by the Healthcare Products Regulatory Agency (MHRA) in the UK. EMBRACE is the second study in Cybin’s PARADIGM program to assess the effectiveness of CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD). CYB003 is a proprietary analogue of psilocin, the active ingredient in “magic mushrooms”.

EMBRACE will enrol 330 participants who live with moderate to severe MDD, whose symptoms are not adequately managed by traditional antidepressant treatments. This move ahead is supported by the promising Phase 2 data, which showed that 71% of participants treated with CYB003 were in full remission from their symptoms. 100% of participants responded to treatment at 12 months, after only two 16mg doses of CYB003. The primary goal of Phase 3 is to measure CYB003 against a placebo against the change in depressive symptoms six weeks following the initial dose.

The complete PARADIGM program will consist of 550 participants worldwide, with roughly 105 clinical sites in the US, Europe, the UK, and Australia. Thus far, conclusions are very positive, but Cybin does urge some caution, describing their conclusions so far, and future plans, as “forward-looking statements”, also stating that:

The efficacy of [psychedelics] has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition.

The Minnesota Psychedelic Medicine Task Force

Minnesota’s Psychedelic Medicine Task Force (PMTF) has recommended a comprehensive framework for legal, regulated access to psychedelic substances. It was established in 2023 to advise the Minnesota legislature of the legal, medical, and policy issues associated with the potential legalisation of psychedelic medicine.

The task force proposed a multi-faceted approach:

Decriminalisation of psychedelics (this only refers to psilocybin, LSD, and MDMA).
Establishment of a state-regulated clinical program.
Increased funding for psychedelic research.
Creating a state-regulated market for adult use of psilocybin mushrooms.

These recommendations aim to more accurately align health and safety, individual freedom, and wider access to potentially beneficial treatments. The medicinal element of the proposed changes would allow for the therapeutic use of psychedelics under qualified medical supervision. The decriminalisation aspect of the recommendations would remove criminal penalties solely for possession and personal use.

By advocating for a regulated market for adult use of these substances, the task force is reflecting a growing national (and broadly international) trend towards reviewing and altering the legal status and potential medicinal applications of psychedelics. This underscores the need for increased research into, and better understanding of, the effects of these substances to further guide policy in the future.

Psychedelics Beneficial for the Clergy?

A recent study published in Psychedelic Medicine has revealed that psychedelic-naive religious leaders who participated in just two guided psilocybin sessions reported many positive changes. The study was carried out by Roland R. Griffiths and colleagues at Johns Hopkins University and involved 33 individuals holding well-known leadership positions within a variety of established religious bodies. Participants reported a perceived increase in their effectiveness in their religious roles, as well as improvements in their general well-being. When reviewed after six months following the second psilocybin session, participants confirmed the changes were still present. They reported more positive attitudes towards their faith itself, and further enhancements to their leadership abilities and religious practices.

All of these changes were largely sustained on a second 16-month follow-up. 96% of participants rated at least one of their psilocybin experiences as one of the top five most spiritually significant experiences of their lives. 92% described experiences as profoundly sacred, 83% psychologically insightful, and 79% psychologically meaningful.

The study authors concluded that:

In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.

So, while the results initially appear exceedingly positive, as ever with our early forays into the study of psychedelics, we must proceed with caution.

Experimental Psychedelics for Life-Threatening Diagnoses

Researchers at the University of New Mexico (UNM) are joining a multi-site clinical trial of an experimental drug, RE104, which is designed to assist patients with the trauma of receiving a life-threatening diagnosis. The REKINDLE trial will test the drug’s efficacy for patients diagnosed with conditions like cancer, ALS, multiple sclerosis, and Parkinson’s disease.

RE104 is a synthetic drug which is chemically similar to psilocybin. The psychedelic effects of the substance are designed to have a shorter duration – about three hours, as opposed to the 6-7 hours usually associated with psilocybin. The theory is that this could maintain the potential therapeutic benefits of psilocybin, but make the experience much more manageable.

The study aims to build upon existing research showing the benefits of psychedelic substances to tackle the symptoms of depression and anxiety. If successful, this could offer a new approach to palliative care. Lawrence Leeman of UNM explains:

This has the potential to alter the process of death and dying for a lot of people. A lot of us would probably agree that the fear of death in our society is very strong and often the way of dying is often very hard. If this is successful, it offers all sorts of different possibilities.

Psychedelics Help LGBTQ+ Identity and Wellbeing

A study of LGBTQ+ individuals who have used psychedelics has concluded that their experiences can significantly improve their mental health. The study, published in the Journal of Psychoactive Drugs, found that these effects helped to foster greater self-acceptance of their gender and sexual identities.

The study surveyed 346 people who identified across a diverse gender spectrum. A significant majority, 77.2%, believed in the potential of psychedelics to alleviate gender dysphoria. 65.3% reported that their experiences actively influenced their attitudes towards their gender identity. The research documented large reductions in symptoms of traumatic stress, anxiety, and depression, and a major increase in psychological flexibility.

Perhaps the most significant finding was the strong correlation between the reported intensity of the psychedelic experience and the perceived positive outcomes in self-acceptance and free exploration of identity. This suggests, perhaps, that the experience of ego-death or dissolution associated with high-dose psychedelics may be the reason for these lasting psychological changes following the experience. If this is the case, and higher doses do equal more pronounced benefits, it highlights the continuing importance of set and setting in future clinical sessions. Higher doses and the resulting ego-shattering experiences can be extremely challenging, so our therapeutic environments must have adequate controls in place to manage these challenges.

Australia’s Clinical Practice Guideline for MDMA

In 2023, Australia became the first country to reschedule MDMA from a prohibited to a controlled substance. Australia’s first clinical practice guideline for psychedelic-assisted therapy has been released for public review. Developed by Monash University, Melbourne, the guideline explains the appropriate clinical use of MDMA as an adjunct to the treatment of persistent PTSD.

The Guideline Development Group, which consisted of a diverse group of experts in fields such as neuroscience and psychiatry, as well as representatives from government agencies, non-profit, and consumer organisations, conditionally recommended against the routine use of MDMA for PTSD. However, the guideline does outline specific, controlled situations in which the substance could be administered. The document provides recommendations for both current clinical practice and future areas of possible research. The draft is open for comment from the public until 05/09/2025.

Rising Ketamine Addiction in the UK

A leading UK drugs expert has highlighted the growing issue of ketamine addiction, highlighting a major dilemma as researchers launch a new trial to test the drug’s effectiveness in treating chronic alcoholism. Professor Celia Morgan, of the University of Exeter’s Psychedelic Studies Transdisciplinary Research Group, is leading a Phase 3 clinical trial for ketamine-assisted therapy. The combination appears to hold significant promise for individuals with treatment-resistant addiction. However, Morgan highlights the risk of the surge of recreational misuse of ketamine, which can lead to serious health issues. Increasing calls for stricter regulation of the substance could significantly impact research efforts.

The rise in recreational use has prompted a political push for ketamine’s reclassification to a Class A substance, which would place it alongside psilocybin and MDMA. As we know, the legal barriers to research have hamstrung our efforts to understand the potential benefits of every psychedelic. Professor Morgan warns that while stricter regulation may be intended to protect the public, it may well have the opposite effect. If promising therapies such as ketamine for alcoholism are halted as a result, then in the long run, we may miss out on potentially breakthrough treatments and actively harm the public good.

The Brain on Psychedelics: Psilocybin vs Ketamine

The hypothalamus is a deep brain region that is crucial for regulating fundamental processes like mood, hunger, and stress. A recent study in the Journal of Psychopharmacology has investigated the effects of both psilocybin and ketamine on the rat hypothalamus. The researchers analysed changes in the production of brain messenger molecules (neuropeptides) after each drug was administered, finding some marked differences.

Psilocybin

A single high dose of psilocybin was seen to promote widespread changes in the hypothalamus. It increased the activity of a variety of neuropeptides involved in both mood and appetite. This suggests it has a rather broad effect on these signal pathways. Interestingly, it also decreased the production of one specific neuropeptide associated with appetite suppression – further evidence of a broad, wide-ranging effect on the brain. These findings offer some underpinning for how psilocybin might be used to treat conditions like depression or anorexia, by directly affecting the circuits that govern emotion and food intake.

Ketamine

In contrast to psilocybin, ketamine’s effects were markedly more focused. They had a much more limited, targeted effect on neuropeptides in the hypothalamus. Ketamine is well known for its rapid antidepressant effects. This research suggests that while their therapeutic effects may have some perceived similarities, ketamine’s mechanism of action within this specific brain region is very different to that of psilocybin.

Once again, this study highlights the importance of further research and understanding as it illustrates plainly that not all psychedelics affect the brain in the same way, even if they can produce similar outcomes, in combination with therapy.

Final Thoughts

The sheer volume of new research and policy updates of late shows just how rapidly the landscape of psychedelic medicine – and perception of psychedelics in all contexts – is evolving. There is immense and growing promise, but many difficulties and barriers to genuine progress persist. With cautious optimism, we will continue to monitor these developments as they unfold.

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to Sam via email at samwoolfe@gmail.com

share your toughts

Join the Conversation.

0 Comments

Inline Feedbacks

View all comments

9 minute read

In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the 'weird'. Sam Woolfe applies Fisher's analysis to psychedelic states.

09 Feb, 2026

Opinion | Psychedelics and Mark Fisher’s Theory of the Weird

Sam Woolfe

13 minute read

Un aperçu objectif du protoxyde d'azote, examinant sa normalisation croissante, ses effets puissants, son attrait, ses risques et son histoire.

07 Feb, 2026

Guides | Le gaz hilarant : Le protoxyde d’azote (N2O)

Nuit

13 minute read

Nuit compare les expériences de LSA issues de deux sources de semences, contextualisées par l'histoire et la science, dans le but de présenter une vision équilibrée des effets variables, des incertitudes, des risques et des enseignements de la LSA.

05 Feb, 2026

Personal Stories | Le LSA : la version naturelle du LSD ?

Nuit

12 minute read

Stroke, traumatic brain injury, and neurodegenerative diseases are leading, interconnected causes of global disability and economic burden with limited effective treatments. Sam Gandy highlights the potential of psychedelics as novel therapies to promote brain repair and recovery.

03 Feb, 2026

Science | Can Psychedelics Help Mend Broken and Ailing Brains?

Sam Gandy

11 minute read

The ancient, subterranean networks of fungi underpin life on Earth and are now emerging as a powerful foundation for future sustainable biotechnologies.

01 Feb, 2026

Science | Beyond the Trip: How Fungi Are Engineering Our Future

David Blackbourn

8 minute read

Dans la deuxième partie de ce guide sur l'influence du dosage sur les expériences psychédéliques, Eliacide examine les combinaisons de drogues et les expériences qui ne visent pas à dissoudre l'ego.

30 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 2)

Eliacide

9 minute read

Eliacide explique que le dosage des médicaments est très subjectif et doit être choisi en fonction du niveau d'expérience personnel et du contexte souhaité, avertissant que les débutants doivent éviter les doses élevées et encourageant les individus à trouver leur propre « juste milieu » plutôt que de considérer tout conseil comme absolu.

28 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 1)

Eliacide

9 minute read

Real-world data confirms the extremely low physical risk of psychedelics; the NHS and FDA intensify their scrutiny of clinical rollout; and we see expanding legal momentum in the US, as well as a shift towards shorter-acting compounds and even non-hallucinogenic, virtual alternatives.

26 Jan, 2026

All Articles | PSYCH NEWS – 26/01/2026

David Blackbourn

12 minute read

Nuit s'entretient avec Andrés Gómez, chercheur en conscience à l'Institut de recherche Qualia, qui fait le lien entre la science informatique, les récits expérientiels, les traditions contemplatives orientales et la recherche psychédélique.

25 Jan, 2026

Personal Stories | Mon échange avec le chercheur Andrés Gómez Emilson

Nuit

10 minute read

John Robertson offers a practical guide to understanding the causes of non-responses to psychedelics and what to do to move beyond them safely and effectively.

24 Jan, 2026

Guides | The ‘Nada’ Experience: What To Do When Psychedelics Don’t Work (Part 2)

John Robertson

7 minute read

Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use.

22 Jan, 2026

Opinion | (Anti)prohibition, Psychonautics, and Designer Drugs

Alfredo Squillaro

11 minute read

Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a healthy relationship with the self that allows it to soften, open, and connect with others.

20 Jan, 2026

Self-Development | Discovering the Authentic Self Through Psychedelics

Oli Genn-Bash

9 minute read

Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness.

18 Jan, 2026

Opinion | Dionysian Cults and Free Parties

Alfredo Squillaro

13 minute read

Nuit décrit son expérience du 2C-P comme un psychédélique puissant, à action lente et prolongée, appartenant à la famille des 2C-x – davantage comparable à une longue et exigeante randonnée qu'à un simple voyage.

16 Jan, 2026

Personal Stories | 2C-P : La charrette psychédélique

Nuit

11 minute read

Can psychedelics genuinely challenge and undermine the military-industrial complex by transforming consciousness, or do they risk being co-opted to merely help individuals psychologically adapt to an inherently violent and unjust system?

14 Jan, 2026

Opinion | Decentralised Minds: Can Psychedelics Undermine the Military Industrial Complex?

Oli Genn-Bash

11 minute read

Oli Genn-Bash explores the growing popularity of functional mushrooms, blending personal experience, research, and traditional perspectives to argue for a more holistic, respectful understanding of fungi.

12 Jan, 2026

Opinion | A Holistic and Spiritual Approach to Functional Mushrooms

Oli Genn-Bash

11 minute read

Despite bold promises surrounding psychedelics, a significant share of patients fail to meaningfully improve, revealing that non-response is a central – and often overlooked – challenge in psychedelic therapy.

10 Jan, 2026

Science | Let’s Talk About Non-Responders in Psychedelic Therapy

Ed Prideaux

8 minute read

Psychedelic use is commonly divided into spiritual, therapeutic, and recreational categories whose meanings are unclear and unevenly valued, with recreational use often stigmatised despite having aspects that deserve reconsideration.

08 Jan, 2026

Opinion | In Defence of Recreational Psychedelic Use

Annabelle Abraham

15 minute read

The Immortality Key builds a sweeping psychedelic-religion narrative on evidence that its own primary scientific authority later rejected as methodologically flawed, undermining the book’s credibility despite its popular success.

06 Jan, 2026

History | Psychedelic Bullshit? An Evaluation of The Immortality Key

Ed Prideaux

10 minute read

Over the past year, the psychedelic field has seen unprecedented scientific and regulatory advances collide with bureaucratic barriers and venture capital pressures, revealing both rapid progress toward medical integration and the fragility – and cultural tension – of an emerging industry at a pivotal moment.

04 Jan, 2026

News & Updates | PSYCH NEWS 2025 – THE YEAR IN REVIEW

David Blackbourn

8 minute read

Martha Allitt unpacks the history of MK-ULTRA, a secret CIA program that conducted unethical experiments with LSD, hypnosis, and other techniques in an attempt to develop methods of mind control and psychological manipulation during the Cold War.

04 Jan, 2026

History | MK-ULTRA: A Macabre History of LSD and Mind Control

Martha Allitt

16 minute read

Ed Prideaux examines Elon Musk’s alleged drug use and public behaviour in the context of his immense political and technological influence.

02 Jan, 2026

Opinion | High on Power: How Much Does Ketamine Explain Elon Musk’s Erratic Behaviour?

Ed Prideaux

10 minute read

Psychedelics can help us rethink the “hard problem” of consciousness by challenging the materialist view that the brain generates experience.

30 Dec, 2025

Philosophy | Psychedelics and the Hard Problem of Consciousness

David Blackbourn

12 minute read

Nuit décrit le 2C-C comme un membre subtil et apaisant de la famille 2C-X, qui évoque de doux souvenirs d'expériences sereines et introspectives.

28 Dec, 2025

Guides | 2C-C : la version Stone du 2C-B ?

Nuit

4 minute read

Theories suggest that N,N-dimethyltryptamine (DMT) is released in our brains when we die – but what do we really know about this potent psychedelic and its endogenous role in the human body?

22 Dec, 2025

Science | The Endogenous DMT Narrative: Separating Fact From Fiction

Stephanie Price

11 minute read

While psychedelics get most of the limelight in discussions about altered states of consciousness, such states can also be accessed through more accessible and potentially safer means, particularly sound baths.

20 Dec, 2025

Spirituality | Sound Baths and Altered States

Oli Genn-Bash

9 minute read

David Blackbourn explores the history and present-day use of psychoactive substances in the Middle East, including the religious, social, and political factors that have influenced this usage.

18 Dec, 2025

History | Contemporary Psychoactive Drug Use in the Middle East

David Blackbourn

8 minute read

Iboga, a West African shrub traditionally used in the Bwiti spiritual tradition, is now being used for microdosing in the West.

16 Dec, 2025

Personal Stories | Microdosing Iboga: Why People Are Taking Tiny Amounts of a Hallucinogenic Shrub

Martha Allitt

5 minute read

Clinical trials typically evaluate psychedelics through short-term before-and-after measures to assess treatment efficacy, but longer-term and lifelong effects are harder to quantify.

14 Dec, 2025

Self-Development | The Long-Term Effects of Psychedelics Are Sometimes Ambiguous

Annabelle Abraham

11 minute read

While psychedelic insights may be valuable, they can be difficult to interpret and require a broader psychological, spiritual, philosophical, or cultural framework to determine whether they reflect genuine truth or mere subjective experience.

12 Dec, 2025

Self-Development | Psychedelics and Epistemic Authority: How Can We Trust Psychedelic Insights?

Oli Genn-Bash

Our Products

Related Products

SALE! -35%

1V-LSD 150mcg Blotters From

(145)

1cP-LSD 100mcg Blotters From 18.00

(137)

Tryptamine Mix and Match Pack (4 x 0.1g) €65.00

(1)

SALE! -35%

1V-LSD 10mcg Micro Pellets From

(44)

SALE! -35%

1V-LSD 225mcg Art Design Blotters From

(62)

1S-LSD 150mcg Blotters From 29.00

(18)

1cP-LSD 150mcg Art Design Blotters From 25.00

(74)

SALE! -35%

1V-LSD 225mcg Pellets From

(26)

1cP-LSD 10mcg Micro Pellets From 15.00

(23)

1D-LSD 225mcg Pellets (1T-LSD) From 42.00

(13)

5-MeO-DMT Freebase From 23.95

(36)

1S-LSD 10mcg Micro Pellets €20.00

(3)

O-PCE HCL From 17.50

(25)

1cP-LSD 20mcg Micro Blotters From 18.00

(28)

1cP-LSD 150mcg Pellets From 25.00

(13)

see all products

Earn
Affiliates

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Comment on an article

50

Check out our Community Blog and get involved with the conversation. You will be awarded 50 x ChemCoins for each comment up to a limit of 250 total ChemCoins.
Leave a product review

50

Have you purchased any of our products? Reviews and reports are so important to the community. Share your honest opinion, and we’ll reward you with 50 ChemCoins for each review!
Complete an order

X

Every time you complete an order with us, you’ll be awarded ChemCoins for each Euro spent.

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Become an affiliate!

Earn commission every time someone makes a purchase through your link.

When you become an affiliate, you will be allocated a unique link to share with your friends, followers, subscribers, or Aunt Susan.

You can choose to payout the commission earned once per month, or save it up to receive on a rainy day! Commission earned is 5% of the total order value per referral.

Contact us to join the Chemical Collective family and become an affiliate.

Welcome toChemical Collective

PSYCH NEWS – 11/08/2025

By David Blackbourn

in this article

By David Blackbourn

CYB003 Receives Regulatory Approval for MDD

The Minnesota Psychedelic Medicine Task Force

Psychedelics Beneficial for the Clergy?

Experimental Psychedelics for Life-Threatening Diagnoses

Psychedelics Help LGBTQ+ Identity and Wellbeing

Australia’s Clinical Practice Guideline for MDMA

Rising Ketamine Addiction in the UK

The Brain on Psychedelics: Psilocybin vs Ketamine

Psilocybin

Ketamine

Final Thoughts

By David Blackbourn

share your toughts

Join the Conversation.

Related articles

Related Products

Reward program

Comment on an article

Leave a product review

Complete an order

Become an affiliate!

Welcome to
Chemical Collective